How to buy Cyteir Therapeutics IncCommon Stock (CYT) stock

Cyteir Therapeutics, Inc. Common Stock is a biotechnology business based in the US. Cyteir Therapeutics IncCommon Stock shares (CYT) are listed on the NASDAQ and all prices are listed in US Dollars. Cyteir Therapeutics IncCommon Stock employs 25 staff and has a market cap (total outstanding shares value) of 0.00.

Cyteir Therapeutics IncCommon Stock stock price (NASDAQ: CYT)

Use our graph to track the performance of CYT stocks over time.

Cyteir Therapeutics IncCommon Stock shares at a glance

• Key figures

Information last updated 2021-07-23.

52-week range	$14.00 - $23.10
50-day moving average	$18.35
200-day moving average	$18.35
Wall St. target price	N/A
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	N/A

Buy Cyteir Therapeutics IncCommon Stock shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Cyteir Therapeutics IncCommon Stock stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Cyteir Therapeutics, Inc. Common Stock by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Cyteir Therapeutics IncCommon Stock financials

Gross profit TTM	$-16,591,000
Return on assets TTM	0%
Return on equity TTM	0%
Profit margin	0%
Book value	N/A
Market capitalisation	$529.8 million

TTM: trailing 12 months

Shorting Cyteir Therapeutics IncCommon Stock shares

There are currently 31,739 Cyteir Therapeutics IncCommon Stock shares held short by investors – that's known as Cyteir Therapeutics IncCommon Stock's "short interest". This figure is up from 0 last month.

There are a few different ways that this level of interest in shorting Cyteir Therapeutics IncCommon Stock shares can be evaluated.

Cyteir Therapeutics IncCommon Stock's "short interest ratio" (SIR)

Cyteir Therapeutics IncCommon Stock's "short interest ratio" (SIR) is the quantity of Cyteir Therapeutics IncCommon Stock shares currently shorted divided by the average quantity of Cyteir Therapeutics IncCommon Stock shares traded daily (recently around 352655.55555556). Cyteir Therapeutics IncCommon Stock's SIR currently stands at 0.09. In other words for every 100,000 Cyteir Therapeutics IncCommon Stock shares traded daily on the market, roughly 90 shares are currently held short.

To gain some more context, you can compare Cyteir Therapeutics IncCommon Stock's short interest ratio against those of similar companies.

• Sonnet BioTherapeutics (SONN.US): 1.11
• PDS Biotechnology Corporation (PDSB.US): 0.41
• Vertex Pharmaceuticals Incorporated (VRTX.US): 1.3

However Cyteir Therapeutics IncCommon Stock's short interest can also be evaluated against the total number of Cyteir Therapeutics IncCommon Stock shares, or, against the total number of tradable Cyteir Therapeutics IncCommon Stock shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Cyteir Therapeutics IncCommon Stock's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Cyteir Therapeutics IncCommon Stock shares in existence, roughly 0 shares are currently held short) or 0.0425% of the tradable shares (for every 100,000 tradable Cyteir Therapeutics IncCommon Stock shares, roughly 43 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Cyteir Therapeutics IncCommon Stock.

Find out more about how you can short Cyteir Therapeutics IncCommon Stock stock.

Cyteir Therapeutics IncCommon Stock share dividends

We're not expecting Cyteir Therapeutics IncCommon Stock to pay a dividend over the next 12 months.

Cyteir Therapeutics IncCommon Stock overview

Cyteir Therapeutics, Inc. operates as a clinical-stage oncology company that develops novel therapeutics based on the biology of DNA repair for the treatment of cancer and synthetic lethality therapeutics for autoimmune diseases. The company engages in manufacturing therapeutics that provide precision targeting of key DNA repair factors to induce diseased cells to self-destruct by DNA damage overload and uses an integrated drug development platform that modulates the imbalance between DNA damage and repair for the therapeutic effect to deliver a pipeline of small molecule therapeutics with a range of potential disease state applications. It provides CYT-0851, an oral small-molecule inhibitor of RAD51-mediated DNA repair. It focuses on providing treatments for a range of hematological malignancies, solid tumors, and chronic autoimmune disorders. The company was incorporated in 2012 and is based in Lexington, Massachusetts. .

Frequently asked questions

What percentage of Cyteir Therapeutics IncCommon Stock is owned by insiders or institutions?
Currently 4.385% of Cyteir Therapeutics IncCommon Stock shares are held by insiders and 38.43% by institutions. How many people work for Cyteir Therapeutics IncCommon Stock?
Latest data suggests 25 work at Cyteir Therapeutics IncCommon Stock. When does the fiscal year end for Cyteir Therapeutics IncCommon Stock?
Cyteir Therapeutics IncCommon Stock's fiscal year ends in December. Where is Cyteir Therapeutics IncCommon Stock based?
Cyteir Therapeutics IncCommon Stock's address is: 128 Spring Street, Lexington, MA, United States, 02421